TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN) Insider MonkeyMyriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum Yahoo FinanceCompared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics NasdaqMyriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth Seeking AlphaWhy Is Myriad Genetics (MYGN) Stock Soaring Today FinancialContent
